ONCOLOGY Nurse Edition October 2008, Vol 22 No 11

Publication
Article
Oncology Nurse EditionONCOLOGY Nurse Edition Vol 22 No 11
Volume 22
Issue 11

October 2008, Vol 22 No 11

Main Articles

Psychological Challenges After Cancer: A Guide for Clinical Practice Reviewed in:

The Recklitis et al Article Reviewed

LATE EFFECTS CLINIC: Post-Trauma Symptoms in Cancer Survivors

Graft-Versus-Host Disease: A Complex Long-Term Side Effect of Hematopoietic Stem Cell Transplant Reviewed in:

The Barton-Burke et al Article Reviewed

DRUG ESSENTIALS: Small Molecule Multitargeted TKI Therapy

PATIENT INFORMATION: Fatigue in People with Cancer

Articles in this issue
The Recklitis et al Article Reviewed
A Challenge of Survivorship-Healing the Mind and Spirit
ONCOLOGY Nurse Edition October 2008, Vol 22 No 11
Addressing Psychological Challenges After Cancer: A Guide for Clinical Practice
Graft-Versus-Host Disease: A Complex Long-Term Side Effect of Hematopoietic Stem Cell
Post-Trauma Symptoms in Cancer Survivors
Small Molecule Multitargeted TKI Therapy
Commentary (Ezzone)-Graft-Versus-Host Disease: A Complex Long-Term Side Effect of Hematopoietic Stem Cell
La fatiga en personas con cáncer
Fatigue in People With Cancer
Recent Videos
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Related Content
The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.

FDA Approves FoundationOne CDx Diagnostic for Tovorafenib in Brain Tumors

Roman Fabbricatore
January 20th 2025
Article

The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Psilocybin May Help Address Cancer-Related Psychological Concerns

Michael P. Bogenschutz, MD
January 20th 2025
Podcast

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

Integrating Psilocybin-Assisted Psychotherapy in Comprehensive Cancer Care

Michael P. Bogenschutz, MD
January 20th 2025
Article

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

Tim Cortese
January 18th 2025
Article

The DCISionRT test has shown to be a significant factor in a clinician’s recommendation on whether a patient with DCIS should receive radiotherapy.

UGN-102 May Be Nonsurgical Alternative to TURBT in Low-grade Bladder Cancer

UGN-102 May Be Nonsurgical Alternative to TURBT in Low-grade Bladder Cancer

Tim Cortese
January 18th 2025
Article

UGN-102 elicited complete responses in 79.6% of patients with non–muscle-invasive bladder cancer at 3 months in the ENVISION trial.